Selected article for: "acute respiratory syndrome and lopinavir sars ritonavir"
Author: Park, Su-Jin; Yu, Kwang-Min; Kim, Young-Il; Kim, Se-Mi; Kim, Eun-Ha; Kim, Seong-Gyu; Kim, Eun Ji; Casel, Mark Anthony B.; Rollon, Rare; Jang, Seung-Gyu; Lee, Min-Hyeok; Chang, Jae-Hyung; Song, Min-Suk; Jeong, Hye Won; Choi, Younho; Chen, Weiqiang; Shin, Woo-Jin; Jung, Jae U.; Choi, Young Ki
Title: Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets
  • Cord-id: l611eisi
  • Document date: 2020_5_22
    • ID: l611eisi
    Snippet: Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral
    Document: Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral candidates for human trials. To this end, the antiviral efficacies of lopinavir-ritonavir, hydroxychloroquine sulfate, and emtricitabine-tenofovir for SARS-CoV-2 infection were assessed in the ferret infection model. While the lopinavir-ritonavir-, hydroxychloroquine sulfate-, or emtricitabine-tenofovir-treated group exhibited lower overall clinical scores than the phosphate-buffered saline (PBS)-treated control group, the virus titers in nasal washes, stool specimens, and respiratory tissues were similar between all three antiviral-candidate-treated groups and the PBS-treated control group. Only the emtricitabine-tenofovir-treated group showed lower virus titers in nasal washes at 8 days postinfection (dpi) than the PBS-treated control group. To further explore the effect of immune suppression on viral infection and clinical outcome, ferrets were treated with azathioprine, an immunosuppressive drug. Compared to the PBS-treated control group, azathioprine-immunosuppressed ferrets exhibited a longer period of clinical illness, higher virus titers in nasal turbinate, delayed virus clearance, and significantly lower serum neutralization (SN) antibody titers. Taken together, all antiviral drugs tested marginally reduced the overall clinical scores of infected ferrets but did not significantly affect in vivo virus titers. Despite the potential discrepancy of drug efficacies between animals and humans, these preclinical ferret data should be highly informative to future therapeutic treatment of COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • activity change and acute respiratory syndrome cov: 1, 2, 3
    • activity inhibit and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity inhibit and acute respiratory syndrome cov: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activity inhibit and lopinavir ritonavir: 1, 2
    • activity inhibit and lopinavir ritonavir protease inhibitor: 1
    • acute respiratory syndrome and adolescent adult: 1, 2, 3, 4, 5
    • acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lopinavir ritonavir oral administration: 1, 2
    • acute respiratory syndrome and lopinavir ritonavir protease inhibitor: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lopinavir ritonavir treat: 1, 2, 3, 4, 5
    • acute respiratory syndrome cov and adolescent adult: 1, 2, 3, 4
    • acute respiratory syndrome cov and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome cov and lopinavir ritonavir oral administration: 1, 2
    • acute respiratory syndrome cov and lopinavir ritonavir protease inhibitor: 1, 2, 3, 4, 5
    • acute respiratory syndrome cov and lopinavir ritonavir treat: 1, 2, 3, 4, 5